Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1995; 26:768-775
© 1995 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matsubara, H
Right arrow Articles by Miyatake, K
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsubara, H
Right arrow Articles by Miyatake, K

Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy

H Matsubara, S Nakatani, S Nagata, F Ishikura, Y Katagiri, T Ohe, and K Miyatake

Department of Medicine, National Cardiovascular Center, Suita, Osaka, Japan.

OBJECTIVES. The purpose of this study was to estimate the effect of disopyramide on left ventricular diastolic function in patients with hypertrophic obstructive cardiomyopathy. BACKGROUND. Although disopyramide has been reported to lessen clinical symptoms in patients with hypertrophic obstructive cardiomyopathy, few data exist regarding its effect on diastolic function in these patients. METHODS. Thirteen patients with hypertrophic cardiomyopathy (six with and seven without left ventricular outflow obstruction) were examined. Before and after intravenous disopyramide, hemodynamic and angiographic studies were performed. RESULTS. In patients with outflow obstruction, pressure gradient at the outflow tract decreased from a mean +/- SD of 100 +/- 45 to 26 +/- 33 mm Hg (p < 0.01). Although systolic function was similarly impaired in both groups, the time constant of left ventricular pressure decay (tau) shortened from 56 +/- 10 to 44 +/- 8 ms (p < 0.01) and the constant of left ventricular chamber stiffness (kc) decreased from 0.049 +/- 0.017 to 0.038 +/- 0.014 m2/ml (p < 0.01) only in patients with outflow obstruction. Shortening in tau correlated best with decrease in left ventricular systolic pressure (r = 0.84, p < 0.01). In contrast, tau was prolonged from 52 +/- 10 to 64 +/- 11 ms (p < 0.01) and kc was unchanged in patients without outflow obstruction. CONCLUSIONS. The primary effects of disopyramide on the hypertrophied left ventricle were negative inotropic and negative lusitropic. However, left ventricular diastolic properties in patients with outflow obstruction were improved with a decrease in outflow pressure gradient. Relief of clinical symptoms in hypertrophic obstructive cardiomyopathy with disopyramide might be due in part to improvement of diastolic function, which appears secondary to the reduction in ventricular afterload.


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, H. Rakowski, et al.
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
J. Am. Coll. Cardiol., December 13, 2011; 58(25): 2703 - 2738.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, H. Rakowski, et al.
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
J. Am. Coll. Cardiol., December 13, 2011; 58(25): e212 - e260.
[Full Text] [PDF]


Home page
CirculationHome page
Writing Committee Members, B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, et al.
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Circulation, December 13, 2011; 124(24): e783 - e831.
[Full Text] [PDF]


Home page
CirculationHome page
Writing Committee Members, B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, et al.
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Circulation, December 13, 2011; 124(24): 2761 - 2796.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
Writing Committee Members:*, B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, et al.
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
J. Thorac. Cardiovasc. Surg., December 1, 2011; 142(6): 1303 - 1338.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
Writing Committee Members:*, B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, et al.
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
J. Thorac. Cardiovasc. Surg., December 1, 2011; 142(6): e153 - e203.
[Full Text] [PDF]


Home page
Heart AsiaHome page
B. B. Siswanto and R. Aryani
Recent advances in diagnosis and management of hypertrophic cardiomyopathy
Heart Asia, July 5, 2010; 1(1): 16 - 19.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. V. Sherrid, O. Wever-Pinzon, A. Shah, and F. A. Chaudhry
Reflections of Inflections in Hypertrophic Cardiomyopathy
J. Am. Coll. Cardiol., July 14, 2009; 54(3): 212 - 219.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll Cardiol IntvHome page
P. Sorajja, R. A. Nishimura, S. R. Ommen, C. S. Rihal, B. J. Gersh, and D. R. Holmes Jr
Effect of Septal Ablation on Myocardial Relaxation and Left Atrial Pressure in Hypertrophic Cardiomyopathy: An Invasive Hemodynamic Study
J. Am. Coll. Cardiol. Intv., October 1, 2008; 1(5): 552 - 560.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. A. Fifer and G. J. Vlahakes
Management of Symptoms in Hypertrophic Cardiomyopathy
Circulation, January 22, 2008; 117(3): 429 - 439.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. V. Sherrid, I. Barac, W. J. McKenna, P. M. Elliott, S. Dickie, L. Chojnowska, S. Casey, and B. J. Maron
Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy
J. Am. Coll. Cardiol., April 19, 2005; 45(8): 1251 - 1258.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, F. J. Ten Cate, et al.
American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines
J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1687 - 1713.
[Full Text] [PDF]


Home page
Eur Heart JHome page
Writing Committee Members, B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, et al.
American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines
Eur. Heart J., November 1, 2003; 24(21): 1965 - 1991.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
I. Ostman-Smith, G.o. Wettrell, and T. Riesenfeld
A cohort study of childhood hypertrophic cardiomyopathy: Improved survival following high-dose beta-adrenoceptor antagonist treatment
J. Am. Coll. Cardiol., November 15, 1999; 34(6): 1813 - 1822.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
T. Tokudome, K. Mizushige, T. Ueda, S. Sakamoto, H. Matsuo, and K. Mizushige
Effect of Disopyramide on Left Ventricular Pressure Gradient in Hypertrophic Obstructive Cardiomyopathy in Comparison with Propranolol: A Case Report
Angiology, April 1, 1999; 50(4): 331 - 335.
[Abstract] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement